Abstract:Objective To detect the CYP2C9 and VKORC1 genetic polymorphism in patients with atrial fibrillation which accepted anticoagulant therapy with Warfarin,analyze the correlations of the CYP2C9 and VKO-RC1 genetic polymorphism with the effective dose and onset time of Warfarin.Methods 222 patients with permanert non-valvular atrial fibrillation were recruited randomly and divided into different groups according to the results of anticoagulant therapy.About the Warfarin drug sensitivity of patient,we defined the low effective dose when accumulated dose of Warfarin less than 12.5 milligrams if international normalized ratio (INR) reached the target value 1.8-3.0,the high effective dose was accumulated dose of Warfarin more than or equal to 12.5 milligrams.According to this,the patients were divided into low effective dose group and high effective dose group.The shot onset time was the onset time of Warfarin less than 10 days if INR reached the target value 1.8-3.0,the long onset time was the onset time more than or equal to 10 days.According to this,the patients were divided into shot onset time group and long onset time group.The correlations of the CYP2C9 and VKORC1 genetic polymorphism with the effective dose and onset time of Warfarin were analyzed.Results (1)The age,serum creatinine(SCr) and the proportion of patients taking beta blockers in low effective dose group were significantly higher than those in high effective dose group (P＜0.05 or 0.01);the body mass index (BMI),white blood cell (WBC) count significandy lower than high effective dose group(P＜0.05);the genetic makeup of CYP2C9 rs1057910 in the two groups was significantly different(P＜0.05).(2)The age,SCr and brain natriuretic peptide (BNP) of patients in shot onset time group were significantly higher than those in long onset time group(P＜0.05 or 0.01);the BMI,WBC and left ventricular ejection fraction (LVEF) significantly lower than long onset time group (P＜0.05 or 0.01);the genetic makeup of VKORC1 rs9923231 and rs10871454 in the two groups were significantly different(P＜0.05 or 0.01).(3) The effective dose of Warfarin in patients with CYP2C9 rs1057910 CA genotype was significantly lower than that with CYP2C9 rs1057910 AA genotype (P＜0.01),the onset time of Warfarin in patients with VKORC1 rs9923231 and rs10871454 CT genotype were significantly lower than those with VKORC1 rs9923231 and rs10871454 TT genotype (P＜0.05 or 0.01).(4)Based on the influence of CYP2C9 and VKORC1 different genotype on Warfarin effective dose and onset time,we defined Warfarin drug sensitivity as highly sensitivity,low sensitivity and routine sensitivity prediction model.Conclusion Combination CYP2C9 and VKORC1 genetic polymorphism with the clinical setting of patients provided a new method for guiding Warfarin anticoagulant therapy rationally in clinic and provided guidance evidence for using genotype to adjust Warfarin dose.

The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol

A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy

Polymorphisms in the Genes for Coagulation Factor II, V, VII in Patients Undergoing Coronary Angiography

Stability of Anticoagulation Following Acenocoumarin in Stroke Patients: Role of Pharmacogenomics and Acquired Factors

Acenocoumarol Pharmacogenetic Dosing Algorithm versus Usual Care in Patients with Venous Thromboembolism: A Randomised Clinical Trial

Research on single nucleotide polymorphism with initial anticoagulative effect and maintenance dose of ;Warfarin

Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.

Impact of VKORC1 Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement--a Systematic Review and Meta Analysis.

The correlation of the Warfarin drug sensitivity with CYP2C9 and VKORC1 genetic polymorphism in patients with atrial fibrillation

Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?

Effect of Multiple Single-Nucleotide Variants in VKORC1 Gene on the Maintenance Doses of Warfarin

Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing

Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients

Acute kidney injury interacts with VKORC1 genotype on initiative warfarin dose among heart surgery recipients: a real-world research

The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study

Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients

Study on the Genetic Polymorphism of VKORC1 in Chinese Han Treated by Warfarin Anticoagulant Therapy

Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients

Influence of CYP4F2 Genotype on Warfarin Dose Requirement–a Systematic Review and Meta-Analysis

Mutant CYP3A4/5 Correlated with Clinical Outcomes by Affecting Rivaroxaban Pharmacokinetics and Pharmacodynamics in Patients with Atrial Fibrillation

To Establish a Method for Detecting Genetic Polymorphism of CYP2C9 1075A>C and VKORC1-1639 G>A and Evaluate the Correlation of SNP with Warfarin Dose